Lawson Macartney - Viking Therapeutics Independent Director
| VKTX Stock | USD 74.74 1.69 2.21% |
Director
Dr. Lawson Macartney, DVM, Ph.D., is an Independent Chairman of the Board of the Company. From January 2017 to June 2017, Dr. Macartney served as CEO of Scout Bio Inc., a gene therapy company developing therapies for companion animals. Dr. Macartney serves on the Board of Dechra PLC, an international animal health pharmaceutical company based in the UK, and on the Supervisory Board of the Netherlands Translational Research Centre, a preclinical biopharmaceutical company based in The Netherlands. He served as President, Chief Executive Officer and a member of the board of directors of Ambrx Inc., a biopharmaceutical company, from February 2013 to June 2015. Prior to Ambrx, Dr. Macartney served at Shire AG, a specialty biopharmaceutical company, as Senior Vice President of the Emerging Business Unit from 2011 to 2013, where he was responsible for discovery initiatives through Phase 3 development of Shires Specialty Pharmaceutical portfolio. Prior to joining Shire AG, he served at GSK, a pharmaceutical company, from 1999 to 2011, serving as Senior Vice President of Global Product Strategy and ProjectPortfolio Management from 2007 to 2011, as Senior Vice President, Cardiovascular and Metabolic Medicine Development Center from 2004 to 2007, and as Vice President, Global Head of Cardiovascular, Metabolic and Urology Therapeutic Areas from 1999 to 2004. Prior to joining GSK, Dr. Macartney was employed at Astra Pharmaceuticals from 1998 to 1999 in leadership roles in operations, marketing and sales, and served as Executive Director, Commercial Operations at AstraMerck, Inc., a pharmaceutical company, from 1996 to 1998 since 2015.
| Age | 60 |
| Tenure | 9 years |
| Address | 9920 Pacific Heights Boulevard, San Diego, CA, United States, 92121 |
| Phone | 858 704 4660 |
| Web | https://www.vikingtherapeutics.com |
Viking Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1278) % which means that it has lost $0.1278 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1755) %, meaning that it created substantial loss on money invested by shareholders. Viking Therapeutics' management efficiency ratios could be used to measure how well Viking Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.3 in 2024. At this time, Viking Therapeutics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 385.6 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 755.8 K in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Dennis Meyer | LSI Industries | 80 | |
| Mary Coe | Merck Company | 54 | |
| Rochelle Lazarus | Merck Company | 71 | |
| Wendell Weeks | Merck Company | 59 | |
| Mark Serrianne | LSI Industries | 67 | |
| Thomas Glocer | Merck Company | 61 | |
| Paul Rothman | Merck Company | 63 | |
| Robert Beech | LSI Industries | 64 | |
| Carlos Represas | Merck Company | 72 | |
| Thomas Cech | Merck Company | 72 | |
| William Harrison | Merck Company | 70 | |
| Patricia Russo | Merck Company | 68 | |
| Craig Thompson | Merck Company | 64 | |
| Gary Kreider | LSI Industries | 78 | |
| Wilfred OGara | LSI Industries | 60 | |
| John Noseworthy | Merck Company | 66 | |
| Kathy Warden | Merck Company | 49 | |
| Leslie Brun | Merck Company | 68 | |
| Robert Steele | LSI Industries | 62 | |
| Inge Thulin | Merck Company | 67 | |
| John Morgan | LSI Industries | 63 | |
Management Performance
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.13 |
Viking Therapeutics Leadership Team
Elected by the shareholders, the Viking Therapeutics' board of directors comprises two types of representatives: Viking Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viking. The board's role is to monitor Viking Therapeutics' management team and ensure that shareholders' interests are well served. Viking Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viking Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Charles Rowland, Director | ||
| Kathy Rouan, Director | ||
| Matthew Singleton, Independent Director | ||
| Stephanie Diaz, IR Contact Officer | ||
| Marianne Mancini, Chief Officer | ||
| Greg Zante, Vice President Finance & Operartions | ||
| Stephen Webster, Independent Director | ||
| Rochelle Hanley, Chief Medical Officer | ||
| Catherine Kelleher, Vice President - Clinical Development | ||
| Lawson Macartney, Independent Director | ||
| Michael Morneau, Vice Administration | ||
| Amy Broidrick, Senior Vice President - Corporate Development | ||
| Hiroko Masamune, Chief Development Officer | ||
| Geoffrey Barker, Senior Development | ||
| Brian Lian, CEO and President and Director | ||
| Gregory Zante, Vice President - Finance and Operations | ||
| Matthew Foehr, Director |
Viking Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Viking Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 7.81 B | ||||
| Shares Outstanding | 110.27 M | ||||
| Shares Owned By Insiders | 6.03 % | ||||
| Shares Owned By Institutions | 72.19 % | ||||
| Number Of Shares Shorted | 11.15 M | ||||
| Price To Earning | (3.17) X | ||||
| Price To Book | 21.71 X | ||||
| EBITDA | (100.83 M) |
Viking Therapeutics Investors Sentiment
The influence of Viking Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Viking. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Viking Therapeutics' public news can be used to forecast risks associated with an investment in Viking. The trend in average sentiment can be used to explain how an investor holding Viking can time the market purely based on public headlines and social activities around Viking Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Viking Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Viking Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Viking Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Viking Therapeutics.
Viking Therapeutics Implied Volatility | 158.72 |
Viking Therapeutics' implied volatility exposes the market's sentiment of Viking Therapeutics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Viking Therapeutics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Viking Therapeutics stock will not fluctuate a lot when Viking Therapeutics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Viking Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Viking Therapeutics' short interest history, or implied volatility extrapolated from Viking Therapeutics options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| CRM | Salesforce | |
| GOOG | Alphabet Inc Class C |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Viking Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Viking Stock please use our How to Invest in Viking Therapeutics guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for Viking Stock analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Viking Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viking Therapeutics. If investors know Viking will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viking Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.92) | Return On Assets (0.13) | Return On Equity (0.18) |
The market value of Viking Therapeutics is measured differently than its book value, which is the value of Viking that is recorded on the company's balance sheet. Investors also form their own opinion of Viking Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viking Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viking Therapeutics' market value can be influenced by many factors that don't directly affect Viking Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viking Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viking Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viking Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.